Table 5.
Logistic regression analysis of demographic and clinical factors associated with receipt of adjuvant and/or neoadjuvant chemotherapy
| Variable | OR a | 95% CI a | Adjusted P a |
|---|---|---|---|
| Age at diagnosis (years) | |||
| <50 |
Referent |
|
|
| 50 to 69 |
0.701 |
0.407 to 1.207 |
0.200 |
| ≥70 |
0.337 |
0.169 to 0.674 |
0.002 |
| Comorbidities | |||
| None |
Referent |
|
|
| One or more |
1.075 |
0.813 to 1.420 |
0.613 |
| Menopausal status | |||
| Premenopause |
Referent |
|
|
| Menopause |
1.319 |
0.773 to 2.249 |
0.310 |
| Residential status | |||
| Rural |
Referent |
|
|
| Urban |
1.265 |
0.979 to 1.633 |
0.072 |
| Tumor size | |||
| ≤2 |
Referent |
|
|
| >2 |
1.266 |
0.888 to 1.804 |
0.192 |
| Lymph node metastasis | |||
| Negative |
Referent |
|
|
| Positive |
1.933 |
1.508 to 2.477 |
<0.001 |
| Distant metastasis |
|
|
|
| Negative |
Referent |
|
|
| Positive |
2.639 |
0.326 to 21.335 |
0.363 |
| Hormone-receptor status | |||
| ER- and PR- |
Referent |
|
|
| ER + and/or PR+ | 1.392 | 0.986 to 1.964 | 0.060 |
aAdjusted using multivariate logistic regression model.
ER, estrogen receptor; PR, progestogen receptor; OR, odds ratios; CI, confidence intervals.